Ergotamine
Dihydroergotamine
Ergotism
Ergonovine
Arteriovenous Anastomosis
Dihydroergocornine
Migraine Disorders
Sumatriptan
Ergot Alkaloids
Suppositories
Methysergide
Moxisylyte
Receptors, Serotonin
The role of free serum tryptophan in the biphasic effect of acute ethanol administration on the concentrations of rat brain tryptophan, 5-hydroxytryptamine and 5-hydroxyindol-3-ylacetic acid. (1/122)
1. Acute administration of ethanol exerts a biphasic effect on the concentrations of rat brain tryptophan, 5-hydroxytryptamine and 5-hydroxyindol-3-ylacetic acid. Both effects are associated with corresponding changes in the availability of circulating free tryptophan. 2. The initial increases in the above concentrations are prevented by ergotamine, are unaltered by allopurinol and are potentiated by theophylline, whereas the later decreases are prevented by both ergotamine and allopurinol. 3. It is suggested that the initial enhancement by ethanol of brain tryptophan metabolism is caused by catecholamine-mediated lipolysis followed by displacement of protein-bound serum tryptophan, whereas the activation of liver tryptophaan pyrrolase, which is produced by the same mechanism, leads to the later decreases in the brain concentrations of tryptophan and its metabolites. 4. The initial effects of ethanol can be reproduced by an equicaloric dose of sucrose, and a comparison of the two treatments alone could therefore be misleading. 5. The effects of ethanol on liver and brain tryptophan metabolism have also been examined in mice, and a comparison of the results with those previously reported suggests that the ethanol effects are strain-dependent. (+info)Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors. (2/122)
The antimigraine drugs methysergide, ergotamine and dihydroergotamine (DHE) produce selective vasoconstriction in the external carotid bed of vagosympathectomized dogs anaesthetized with pentobarbital and artificially respired, but the receptors involved have not yet been completely characterized. Since the above drugs display affinity for several binding sites, including alpha-adrenoceptors and several 5-HT1 and 5-HT2 receptor subtypes, this study has analysed the mechanisms involved in the above responses. Intracarotid (i.c.) infusions during 1 min of methysergide (31-310 microg min(-1)), ergotamine (0.56-5.6 microg min(-1)) or DHE (5.6-31 microg min(-1)) dose-dependently reduced external carotid blood flow (ECBF) by up to 46+/-4, 37+/-4 and 49+/-5%, respectively. Blood pressure and heart rate remained unchanged. The reductions in ECBF by methysergide were abolished and even reversed to increases in animals pre-treated with GR127935 (10 microg kg(-1), i.v.). The reductions in ECBF by ergotamine and DHE remained unchanged in animals pre-treated (i.v.) with prazosin (300 microg kg(-1)), but were partly antagonized in animals pre-treated with either GR127935 (10 or 30 microg kg(-1)) or yohimbine (1000 microg kg(-1)). Pre-treatment with a combination of GR127935 (30 microg kg(-1)) and yohimbine (1000 microg kg(-1)) abolished the responses to both ergotamine and DHE. The above doses of antagonists were shown to produce selective antagonism at their respective receptors. These results suggest that the external carotid vasoconstrictor responses to methysergide primarily involve 5-HT1B/1D receptors, whereas those to ergotamine and DHE are mediated by 5-HT1B/1D receptors as well as alpha2-adrenoceptors. (+info)Alkaloid binding and activation of D2 dopamine receptors in cell culture. (3/122)
Ergot and pyrrolizidine alkaloids, either extracted from endophyte-infected tall fescue, synthesized, or purchased commercially, were evaluated in cultured cells to estimate their binding to the D2 dopamine receptor and subsequent effects on cyclic AMP production in GH4ZR7 cells, transfected with a rat D2 dopamine receptor. Ergopeptide alkaloid (alpha-ergocryptine, bromocryptine, ergotamine tartrate, and ergovaline) inhibition of the binding of the D2-specific radioligand, [3H]YM-09151-2, exhibited inhibition constants (K(I)) in the nanomolar range, whereas dopamine was less potent (micromolar). The lysergic acid amides (ergine and ergonovine) were 1/100th as potent as the ergopeptide alkaloids. Ergovaline and ergotamine tartrate were equally effective in inhibiting vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production, with consistent nanomolar effective concentration (EC50) values. The remaining ergopeptide alkaloids (alpha-ergocryptine and bromocryptine), lysergic acid amides (ergonovine and ergine), and dopamine were 1/100th as potent. Two representative pyrrolizidines, N-formylloline and N-acetylloline, exhibited no binding activity at the D2 dopamine receptor or effects on the cyclic AMP system within the concentration ranges of nanomolar to millimolar. Our results indicate that the commercially available ergot alkaloids ergotamine tartrate and ergonovine may be used interchangeably in the D2 dopamine receptor system to simulate the effects of extracted ergovaline and ergine and to examine responses in receptor binding and the inhibition of cyclic AMP. (+info)Ergocryptine and other ergot alkaloids stimulate the release of [3H]dopamine from rat striatal synaptosomes. (4/122)
Ergocryptine is an ergot alkaloid that affects dopaminergic activity principally by interacting with D2-type receptors. In this study the ability of ergocryptine and several other ergot alkaloids to release [3H]dopamine from isolated nerve endings was demonstrated using in vitro superfusion of rat striatal synaptosomes. Ergocryptine, ergocristine, and bromocryptine produced an elevation in baseline dopamine release of approximately 400% with effective concentrations (EC50) of approximately 30 microM. Ergotamine, ergonovine, ergovaline, and ergocornine were devoid of activity. The time-course of the ergocryptine-stimulated release was relatively slow compared with amphetamine, nicotine, or K+-stimulated [3H]dopamine release; the maximal increase in release required a 5-min treatment. A number of receptor antagonists were examined for their ability to block ergocryptine-stimulated release. Of the dopaminergic, adrenergic, serotonergic, GABA-ergic, and cholinergic antagonists examined, only phentolamine produced a moderate attenuation in evoked release. Omission of Ca++ from the medium did not affect ergocryptine-evoked release. Following ergocryptine treatment, the synaptosomes were fully responsive to other stimulant. The results indicate that, in addition to interacting with dopamine receptors, several ergot alkaloids may produce dopaminergic effects by increasing the release of dopamine from central nerve endings. Several mechanisms to account for the evoked neurotransmitter release are discussed. (+info)Ergotamine in the acute treatment of migraine: a review and European consensus. (5/122)
Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine. From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed. In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions. For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective. (+info)Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. (6/122)
We report a rare case of ergotism related to a single dose of ergotamine tartrate in a man with AIDS being treated with ritonavir. He was treated with a prostacyclin analogue and made a complete recovery. (+info)Physiological responses of Brahman and Hereford steers to an acute ergotamine challenge. (7/122)
Research was conducted to evaluate the sensitivity of Bos indicus and Bos taurus cattle to a tall fescue ergopeptine alkaloid by assessing vital sign responses. Eight Polled Hereford and seven Red Brahman steers received bolus i.v. injections of ergotamine tartrate and saline vehicle in a simple cross-over design. Physiological traits measured 30 min and immediately before and 30, 60, and 90 min after treatment were respiration rate, rectal temperature, skin temperature at the tailhead and tail tip, systolic and diastolic blood pressure, and heart rate. Blood samples were collected immediately before and 105 min after treatments to determine plasma prolactin and cortisol concentrations. Steers were fed a fescue-free diet in drylot. Ambient temperature and relative humidity averaged 31 degrees C and 55%, respectively, during data collection. No breed x treatment x time interactions were apparent for vital signs. The treatment x time interaction was significant (P < .05) for blood pressure and skin temperature. Ergotamine increased (P < .01) blood pressure and decreased (P < .01) skin temperature. The breed x treatment x time interactions were significant for prolactin (P < .1) and cortisol (P < .01). Ergotamine decreased plasma (P < .01) prolactin and increased (P < .01) cortisol concentrations in both breeds, despite some breed variation. Across all traits, Brahman and Hereford steers responded similarly to acute ergotamine exposure, indicating that the breeds are alike in acute sensitivity to a systemically administered ergopeptine alkaloid associated with fescue toxicosis. (+info)Ergotamine alters plasma concentrations of glucagon, insulin, cortisol, and triiodothyronine in cows. (8/122)
Bovine plasma was assayed to determine whether ergotamine, an ergopeptide isolated from endophytic tall fescue, affected cortisol, triiodothyronine, insulin, and glucagon concentrations. In Exp. 1, four heifers received an i.v. bolus injection of ergotamine tartrate (19 microg/kg BW) or saline vehicle in a simple crossover design 2 d after induced luteolysis. Oxytocin (100 USP units) was i.v. administered 4 h after ergotamine or saline. Treatment x time affected (P < .01) respiration rates and plasma concentrations of cortisol, triiodothyronine, insulin, and glucagon. Respiration rates were elevated (P < .01) 2 to 7 h after ergotamine, but they were unchanged after saline. Plasma cortisol concentrations were increased (P < .01) 1 to 3 h after ergotamine but not after saline. Plasma triiodothyronine was elevated 2 h after ergotamine, but it was unchanged in response to saline. Insulin decreased (P < .01) and glucagon increased (P < .01) during the 1st h after ergotamine, but not in response to saline. A second increase (P < .01) of glucagon was observed 3 h after ergotamine. In Exp. 2, six cows were treated with an i.v. bolus injection of ergotamine (20 microg/kg BW) or saline in a simple crossover design 10 d after receiving a s.c. ear implant containing norgestomet. Oxytocin (100 USP units) was i.v. administered 4 h after ergotamine or saline. Treatment x time affected (P < .001) respiration rates, cortisol, insulin, and glucagon and tended to influence (P = .12) triiodothyronine concentrations. Respiration rates were elevated (P < .01) 1 to 7 h after ergotamine but were unaltered by saline. Plasma cortisol was elevated (P < .01) 1 to 5 h after ergotamine, but not in response to saline. Plasma triiodothyronine was elevated (P < .01) 1 to 2 h after ergotamine, but not after saline. Insulin was decreased (P < .01) and glucagon increased (P < .01) within 1 h after ergotamine treatment, but they were not altered by saline. A second increase (P < .01) of glucagon occurred by 4 h after ergotamine. In Exp. 1 and 2, glucagon increased (P < .01) 1 h after oxytocin in saline and ergotamine cows. Results indicate that ergotamine can alter plasma concentrations of hormones that mediate nutrient metabolism and thermoregulation in cattle. (+info)Ergotamine is a type of ergopeptine alkaloid, derived from the ergot fungus (Claviceps purpurea) that parasitizes certain grains, particularly rye. It is a potent vasoconstrictor and has been used medically to prevent migraines and treat cluster headaches, as well as for other uses such as controlling postpartum hemorrhage and reducing symptoms of orthostatic hypotension.
Ergotamine works by binding to serotonin receptors in the brain and causing vasoconstriction of cranial blood vessels, which can help to relieve migraine headaches. However, it can also cause serious side effects such as nausea, vomiting, muscle pain, numbness or tingling in the extremities, and in rare cases, more severe reactions such as ergotism, a condition characterized by vasoconstriction of peripheral blood vessels leading to gangrene.
Ergotamine is usually taken orally, but can also be administered rectally or by inhalation. It is important to follow the dosage instructions carefully and avoid taking excessive amounts, as this can increase the risk of serious side effects. Ergotamine should not be taken during pregnancy or while breastfeeding, and it may interact with other medications, so it is important to inform your healthcare provider of all medications you are taking before starting ergotamine therapy.
Dihydroergotamine is a medication that belongs to a class of drugs called ergot alkaloids. It is a semi-synthetic derivative of ergotamine, which is found naturally in the ergot fungus. Dihydroergotamine is used to treat migraines and cluster headaches.
The drug works by narrowing blood vessels around the brain, which helps to reduce the pain and other symptoms associated with migraines and cluster headaches. It can be administered via injection, nasal spray, or oral tablet. Dihydroergotamine may cause serious side effects, including medication overuse headache, ergotism, and cardiovascular events such as heart attack or stroke. Therefore, it is important to use this medication only as directed by a healthcare provider.
Ergotamines are a type of medication that is derived from the ergot fungus (Claviceps purpurea). They are primarily used to treat migraines and cluster headaches. Ergotamines work by narrowing blood vessels around the brain, which helps to alleviate the symptoms of migraines and headaches.
Ergotamines are available in various forms, including tablets, suppositories, and injectable solutions. They can be taken orally, rectally, or intravenously, depending on the severity of the symptoms and the patient's medical history. Ergotamines should be used with caution, as they can cause serious side effects such as nausea, vomiting, muscle pain, and weakness.
Ergotamines are also used in the treatment of other conditions, including postpartum hemorrhage, heart failure, and high blood pressure during pregnancy. However, their use in these conditions is typically reserved for cases where other treatments have been ineffective or contraindicated.
It's important to note that ergotamines can interact with a variety of medications, including certain antidepressants, antibiotics, and HIV medications. Therefore, it's essential to inform your healthcare provider about all the medications you are taking before starting treatment with ergotamines.
Ergotism is a condition that results from the consumption of ergot alkaloids, which are found in ergot fungus that infects grains such as rye. There are two types of ergotism: convulsive and gangrenous. Convulsive ergotism can cause seizures, muscle spasms, vomiting, and mental disturbances. Gangrenous ergotism, on the other hand, can lead to constriction of blood vessels, resulting in dry gangrene of the extremities, which can ultimately require amputation. Ergotism has been known since ancient times and was once a significant public health problem before modern agricultural practices were implemented.
Ergonovine is a medication that belongs to a class of drugs called ergot alkaloids. It is derived from the ergot fungus and is used in medical settings as a uterotonic agent, which means it causes the uterus to contract. Ergonovine is often used after childbirth to help the uterus return to its normal size and reduce bleeding.
Ergonovine works by binding to specific receptors in the smooth muscle of the uterus, causing it to contract. It has a potent effect on the uterus and can also cause vasoconstriction (narrowing of blood vessels) in other parts of the body. This is why ergonovine is sometimes used to treat severe bleeding caused by conditions such as uterine fibroids or ectopic pregnancy.
Like other ergot alkaloids, ergonovine can have serious side effects if not used carefully. It should be administered under the close supervision of a healthcare provider and should not be used in women with certain medical conditions, such as high blood pressure or heart disease. Ergonovine can also interact with other medications, so it's important to inform your healthcare provider of all medications you are taking before receiving this drug.
An arteriovenous (AV) anastomosis is a connection or short channel between an artery and a vein that bypasses the capillary bed. In a normal physiological condition, blood flows from the arteries to the capillaries, where oxygen and nutrients are exchanged with the surrounding tissues, and then drains into veins. However, in an AV anastomosis, blood flows directly from the artery to the vein without passing through the capillary network.
AV anastomoses can occur naturally or be created surgically for various medical purposes. For example, they may be created during bypass surgery to reroute blood flow around a blocked or damaged vessel. In some cases, AV anastomoses may also develop as a result of certain medical conditions, such as cirrhosis or arteriovenous malformations (AVMs). AVMs are abnormal connections between arteries and veins that can lead to the formation of an AV anastomosis.
It is important to note that while AV anastomoses can be beneficial in certain medical situations, they can also have negative consequences if they occur inappropriately or become too large. For example, excessive AV anastomoses can lead to high-flow shunts, which can cause tissue damage and other complications.
Dihydroergocornine is a semi-synthetic ergot alkaloid, which is derived from the ergot fungus (Claviceps purpurea). It is a mixture of dihydroergocornine and dihydrocryptocornine. Dihydroergocornine acts as a partial agonist at alpha-adrenergic receptors, dopamine receptors, and serotonin receptors.
It has been used in the medical field for its vasoconstrictive properties to manage conditions such as orthostatic hypotension and cerebral vasospasm following subarachnoid hemorrhage. However, due to its potential for serious side effects, including ergotism, it is not commonly used today.
It's important to note that the use of Dihydroergocornine should be under the strict supervision of a medical professional and should only be used when the benefits outweigh the risks.
A migraine disorder is a neurological condition characterized by recurrent headaches that often involve one side of the head and are accompanied by various symptoms such as nausea, vomiting, sensitivity to light and sound, and visual disturbances. Migraines can last from several hours to days and can be severely debilitating. The exact cause of migraines is not fully understood, but they are believed to result from a combination of genetic and environmental factors that affect the brain and blood vessels. There are different types of migraines, including migraine without aura, migraine with aura, chronic migraine, and others, each with its own specific set of symptoms and diagnostic criteria. Treatment typically involves a combination of lifestyle changes, medications, and behavioral therapies to manage symptoms and prevent future attacks.
Sumatriptan is a selective serotonin receptor agonist, specifically targeting the 5-HT1D and 5-HT1B receptors. It is primarily used to treat migraines and cluster headaches. Sumatriptan works by narrowing blood vessels around the brain and reducing inflammation that leads to migraine symptoms.
The medication comes in various forms, including tablets, injectables, and nasal sprays. Common side effects of sumatriptan include feelings of warmth or hotness, tingling, tightness, pressure, heaviness, pain, or burning in the neck, throat, jaw, chest, or arms.
It is important to note that sumatriptan should not be used if a patient has a history of heart disease, stroke, or uncontrolled high blood pressure. Additionally, it should not be taken within 24 hours of using another migraine medication containing ergotamine or similar drugs such as dihydroergotamine, methysergide, or caffeine-containing analgesics.
Ergot alkaloids are a type of chemical compound that is produced naturally by certain fungi belonging to the genus Claviceps. These alkaloids are most famously known for being produced by the ergot fungus (Claviceps purpurea), which infects cereal grains such as rye and causes a condition known as ergotism in humans and animals that consume the contaminated grain.
Ergot alkaloids have a complex chemical structure and can have various effects on the human body. They are known to act as powerful vasoconstrictors, which means that they cause blood vessels to narrow and can increase blood pressure. Some ergot alkaloids also have psychoactive effects and have been used in the past for their hallucinogenic properties.
In modern medicine, certain ergot alkaloids are used in the treatment of various conditions, including migraines and Parkinson's disease. However, these compounds can be highly toxic if not used properly, and their use must be carefully monitored to avoid serious side effects.
A suppository is a solid medicinal formulation, often medicated, that is intended to be introduced into the rectum (rectal suppository), vagina (vaginal suppository), or urethra (urethral suppository) for absorption or for localized effect. Suppositories are designed to melt or dissolve at body temperature and release the active ingredients. They come in various shapes, such as cones, cylinders, or torpedo-shaped, and are typically made from a base of cocoa butter, polyethylene glycol, or other biocompatible materials that allow for controlled drug release. Common uses for suppositories include the treatment of constipation, hemorrhoids, local infections, menstrual cramps, and as an alternative method of administering medication for individuals who have difficulty swallowing pills or prefer not to use oral medications.
Ergolines are a group of ergot alkaloids that have been widely used in the development of various pharmaceutical drugs. These compounds are known for their ability to bind to and stimulate specific receptors in the brain, particularly dopamine receptors. As a result, they have been explored for their potential therapeutic benefits in the treatment of various neurological and psychiatric conditions, such as Parkinson's disease, migraine, and depression.
However, ergolines can also have significant side effects, including hallucinations, nausea, and changes in blood pressure. In addition, some ergot alkaloids have been associated with a rare but serious condition called ergotism, which is characterized by symptoms such as muscle spasms, vomiting, and gangrene. Therefore, the use of ergolines must be carefully monitored and managed to ensure their safety and effectiveness.
Some specific examples of drugs that contain ergolines include:
* Dihydroergotamine (DHE): used for the treatment of migraine headaches
* Pergolide: used for the treatment of Parkinson's disease
* Cabergoline: used for the treatment of Parkinson's disease and certain types of hormonal disorders
It is important to note that while ergolines have shown promise in some therapeutic areas, they are not without their risks. As with any medication, it is essential to consult with a healthcare provider before using any drug containing ergolines to ensure that it is safe and appropriate for an individual's specific needs.
Dibenzylchloroethane is not a medical term or a medication used in medicine. It is an organic compound with the formula (C6H5CH2)2CHCl. This compound is not commonly used in a clinical setting, and it does not have a specific medical definition. If you have any questions about a specific chemical compound or medication, I would be happy to help if you provide more context.
Methysergide is a medication that belongs to a class of drugs called ergot alkaloids. It is primarily used for the prophylaxis (prevention) of migraine headaches. Methysergide works by narrowing blood vessels around the brain, which is thought to help prevent migraines.
The medical definition of Methysergide is:
A semisynthetic ergot alkaloid derivative used in the prophylaxis of migraine and cluster headaches. It has both agonist and antagonist properties at serotonin receptors, and its therapeutic effects are thought to be related to its ability to block the binding of serotonin to its receptors. However, methysergide can have serious side effects, including fibrotic reactions in various organs, such as the heart, lungs, and kidneys, so it is usually used only for short periods of time and under close medical supervision.
Methiothepin is a non-selective, irreversible antagonist of serotonin (5-HT) receptors, particularly 5-HT1, 5-HT2, and 5-HT3 receptors. It has also been found to act as an antagonist at dopamine D2 receptors and histamine H1 receptors. Methiothepin has been used in research to study the roles of serotonin and other neurotransmitters in various physiological processes, but it is not commonly used clinically due to its lack of selectivity and potential for causing severe side effects.
Moxisylyte is a muscle relaxant that is primarily used in the form of a topical cream or ointment to help relieve pain and discomfort associated with minor strains, sprains, and bruises. It works by blocking the signals that are sent from the nerves to the brain, which can help to reduce the sensation of pain. Moxisylyte is also known as a vasodilator, meaning that it causes the blood vessels to widen, which can improve blood flow and help to promote healing in the affected area. It is important to note that moxisylyte is not typically used as an oral medication, and it should only be used under the guidance of a healthcare professional.
Serotonin receptors are a type of cell surface receptor that bind to the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). They are widely distributed throughout the body, including the central and peripheral nervous systems, where they play important roles in regulating various physiological processes such as mood, appetite, sleep, memory, learning, and cognition.
There are seven different classes of serotonin receptors (5-HT1 to 5-HT7), each with multiple subtypes, that exhibit distinct pharmacological properties and signaling mechanisms. These receptors are G protein-coupled receptors (GPCRs) or ligand-gated ion channels, which activate intracellular signaling pathways upon serotonin binding.
Serotonin receptors have been implicated in various neurological and psychiatric disorders, including depression, anxiety, schizophrenia, and migraine. Therefore, selective serotonin receptor agonists or antagonists are used as therapeutic agents for the treatment of these conditions.
Vasoconstrictor agents are substances that cause the narrowing of blood vessels by constricting the smooth muscle in their walls. This leads to an increase in blood pressure and a decrease in blood flow. They work by activating the sympathetic nervous system, which triggers the release of neurotransmitters such as norepinephrine and epinephrine that bind to alpha-adrenergic receptors on the smooth muscle cells of the blood vessel walls, causing them to contract.
Vasoconstrictor agents are used medically for a variety of purposes, including:
* Treating hypotension (low blood pressure)
* Controlling bleeding during surgery or childbirth
* Relieving symptoms of nasal congestion in conditions such as the common cold or allergies
Examples of vasoconstrictor agents include phenylephrine, oxymetazoline, and epinephrine. It's important to note that prolonged use or excessive doses of vasoconstrictor agents can lead to rebound congestion and other adverse effects, so they should be used with caution and under the guidance of a healthcare professional.
Ergotamine
Dihydroergotamine
Antimigraine drug
Postpartum bleeding
List of designer drugs
Neuroenhancement
Ergoloid
Bellergal
Nicergoline
Nootropic
Serotonin receptor agonist
Terguride
Glossary of equestrian terms
Sandoz
Novartis
Porphyria
Dancing plague of 1518
Cluster headache
Migraine treatment
5-HT5B receptor
Karl Spiro
Agroclavine
Headache
Adelheid Kofler
Lolitrem B
Methysergide
Fungi in art
Migraine
Caffeine
Medicinal fungi
Ergotamine - Wikipedia
Ergotamine Tartrate And Caffeine Description
Ergotamine - Janusinfo.se
Ergotamine tartrate | CAS 379-79-3 | Tocris Bioscience
Ergotamine tartrate, Ergoline? <...
Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature
Erowid.org: Erowid Reference 6234 : Drug points: severe ergotism associated with interaction between ritonavir and ergotamine :...
Erowid.org: Erowid Reference 6237 : Ergotism related to concurrent administration of ergotamine tartrate and indinavir :...
Discover BiopureTM Ergotamine - 100 µg/mL dried down at Romer Labs
Ergomar (ergotamine) dosing, indications, interactions, adverse effects, and more
Ergotamine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose | Drug Index |...
ERGOTAMINE TARTRATE
Nitrostat (Nitroglycerin): Uses, Dosage, Side Effects, Interactions, Warning
Ergotamine-Induced Takotsubo Cardiomyopathy. - PDF Download Free
commande Ergotamine Tartrate, Ergotamine tartrate australia - AMDI Network
DailyMed - ERY-TAB- erythromycin tablet, delayed release
DailyMed - NITROLINGUAL- nitroglycerin spray
Neurologic Disease and Pregnancy: Overview, General Considerations, New-Onset Neurologic Complications
An unusual cause of chest pain: Acute coronary syndrome following administration of ergotamine tartrate | AVESİS
Dust (Kay Scarpetta Series #21) by Patricia Cornwell, Hardcover | Barnes & Noble®
Ranolazine Advanced Patient Information - Drugs.com
Sumatriptan (Transdermal Route) Before Using - Mayo Clinic
Selpercatinib (Oral Route) Description and Brand Names - Mayo Clinic
Toxins | Free Full-Text | Multi-Mycotoxin Screening Reveals the Occurrence of 139 Different Secondary Metabolites in Feed and...
Neurologic Disease and Pregnancy: Overview, General Considerations, New-Onset Neurologic Complications
British Medical Journal: 2 (5420) | The BMJ
Ergomar - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol | RxWiki
Caffeine12
- In the United States, ergotamine is available as a suppository, a sublingual tablet, and a tablet, sometimes in combination with caffeine. (wikipedia.org)
- The suppository is available under the brand name Migergot, which contains 2 mg of ergotamine with 100 mg caffeine. (wikipedia.org)
- The combination tablet in combination with caffeine called Cafergot contains 1 mg of ergotamine and 100 mg of caffeine. (wikipedia.org)
- The combination of ergotamine tartrate and caffeine prevents blood vessels in your head form expanding and causing migraine headaches. (stason.org)
- The combination of ergotamine tartrate and caffeine comes in the form of tablets and rectal suppositories. (stason.org)
- 1. Although side effects from ergotamine tartrate with caffeine are not common, they can occur. (stason.org)
- 1. Before you take ergotamine tartrate and caffeine, tell your doctor what prescription and nonprescription drugs you are taking, especially erythromycin, nifedipine, prazosin, and propranolol. (stason.org)
- Fass environmental information for Anervan Novum (ergotamine, chlorcyclizine and caffeine) (downloaded 2018-08-20). (janusinfo.se)
- Ergotamine (as the tartrate salt) is used in some migraine medications, Cafergot is the main brand name I believe, contains caffeine and ergotamine. (chemicalforums.com)
- He took 2 tablets daily of Gynergene caf in (Novartis Pharma, SA, Rueil-Malmaison, France) [1 mg of ergotamine tartrate and 100 mg of caffeine] from June 30 to July 1. (erowid.org)
- Making it also inform consumers, recommending or understanding the buy ergotamine tartrate caffeine tablets. (pimpinanmedia.com)
- The combination of ergotamine and caffeine is used to prevent and treat migraine headaches. (nih.gov)
Migraine9
- Mitral and aortic valve disease associated with ergotamine therapy for migraine. (nih.gov)
- Two patients are described in whom severe valvular dysfunction developed during ergotamine therapy for migraine headache. (nih.gov)
- The patient was prescribed ergotamine tartrate for migraine on June 30, 1998. (erowid.org)
- Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. (pediatriconcall.com)
- FDA-labeled indications for ergotamine tartrate are in the abortion or prevention of vascular headaches, such as migraine, migraine variant, cluster headache, and histaminic cephalalgia. (ncats.io)
- She also received ergotamine tartarate 1.5 mg/d for the past 5 days owing to her increased migraine headache. (docksci.com)
- For many years, ergotamine has been used for the acute treatment of migraine. (hacettepe.edu.tr)
- She had a history of severe migraine attacks and started to use ergotamine tartrate 0.75 mg daily the day before. (hacettepe.edu.tr)
- Physicians should be alerted to potential cardiac vasospastic effects of low-dose ergotamine in the treatment of migraine. (hacettepe.edu.tr)
Ergomar1
- The sublingual tablet is available under the brand name Ergomar and contains 2 mg of ergotamine. (wikipedia.org)
Bioavailability of ergotamine2
- The bioavailability of ergotamine is around 2% orally, 6% rectally, and 100% by intramuscular or intravenous injection. (wikipedia.org)
- Ergotamine: increased bioavailability of ergotamine. (nih.gov)
Tartrate salt1
- Ergotamine was introduced into world commerce in 1921, and is currently marketed as its water soluble tartrate salt. (ncats.io)
Toxicity4
- clarithromycin increases toxicity of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- Those with hepatic disease may be at increased risk for developing ergot toxicity due to systemic accumulation of ergotamine. (pediatriconcall.com)
- We present an unusual case of TC in which the possible trigger is ergotamine toxicity. (docksci.com)
- When the drugs she used were analyzed in detail, ergotamine toxicity was seen as a possible etiology. (docksci.com)
Frovatriptan1
- ergotamine, frovatriptan. (medscape.com)
Therapeutic1
- The blood levels of ergotamine-containing drugs are reported to be elevated by the concomitant administration of macrolide antibiotics and vasospastic reactions have been reported with therapeutic doses of the ergotamine-containing drugs when coadministered with these antibiotics. (pediatriconcall.com)
Metabolism3
- Indeed, ritonavir is a potent inhibitor of cytochrome P-450 isoenzymes, mainly CYP3A4,3 which is responsible for the metabolism of ergot.1 Thus, ergot concentrations probably increased to toxic amounts in our patient because ritonavir inhibited ergotamine metabolism. (erowid.org)
- cobicistat will increase the level or effect of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
Eletriptan1
- ergotamine, eletriptan. (medscape.com)
19211
- In 1918 Arthur Stoll patented the isolation of ergotamine tartrate, which was subsequently marketed by Sandoz in 1921. (ncats.io)
Almotriptan1
- ergotamine, almotriptan. (medscape.com)
Alkaloids2
Vasoconstriction1
- It is available in IV or intranasal preparations and tends to cause less arterial vasoconstriction than ergotamine tartrate. (medscape.com)
Ergotism1
- This patient developed severe ergotism after taking 3 mg ergotamine over 5 days, a low dose in terms of the recommended safe dosage of ergot (up to 6 mg a day or 10 mg a week during chronic administration). (erowid.org)
Rectal1
- Oral administration of ergotamine is not as effective as inhaled, rectal, or sublingual administration for treatment of acute cluster attacks. (medscape.com)
Receptors2
- Ergotamine interacts with serotonin, adrenergic, and dopamine receptors. (wikipedia.org)
- Ergotamine is a partial agonist at various tryptaminergic receptors (including the serotonin receptor [5-HT2]) and at various α-adrenergic receptors in blood vessels and various smooth muscles. (ncats.io)
Citations1
- Currently there are no citations for Ergotamine hemitartrate. (tocris.com)
Vascular1
- Ergotamine has been associated with numerous vascular complications but only rarely with fibrosing disorders or valvular heart disease. (nih.gov)
Combination1
- Five days before admission she had begun to take a combination drug (0.3 mg ergotamine tartrate, 0.2 mg belladonna extract, and 20 mg phenobarbital) twice daily for gastric discomfort. (erowid.org)
Effects4
- Side effects of ergotamine include nausea and vomiting. (wikipedia.org)
- ergotamine decreases effects of glyceryl trinitrate pr by pharmacodynamic antagonism. (medscape.com)
- ergotamine decreases effects of nitroglycerin IV by pharmacodynamic antagonism. (medscape.com)
- Ergotamine has alpha-adrenergic antagonist and serotonin antagonist effects and causes constriction of peripheral and cranial blood vessels. (medscape.com)
Include1
- Current sources of ergotamine include the isolation from field ergot and fermentation broth, as well as synthesis via coupling of (+)-lysergic acid with the appropriate synthetic peptidic moiety. (ncats.io)
Interaction1
- We speculate that an interaction between ritonavir and ergotamine was responsible for this case. (erowid.org)
Drug1
- http://neo.pharm.hiroshima-u.ac.jp/drug-info/img/ergotamine.gif Here is the structure of ergotamine itself. (chemicalforums.com)
Years1
- The isolation and naming of ergotamine by Stoll occurred in 1925 but the complete elucidation of structure was not achieved until 1951, with synthesis following some 10 years later. (ncats.io)
Topic1
- Topic: Ergotamine tartrate, Ergoline? (chemicalforums.com)
Review1
- Be the first to review Ergotamine hemitartrate and earn rewards! (tocris.com)
Product1
- Ergotamine is a secondary metabolite (natural product) and the principal alkaloid produced by the ergot fungus, Claviceps purpurea, and related fungi in the family Clavicipitaceae. (wikipedia.org)